At the Canadian Cancer Society, our vision to create a world in which no Canadian fears cancer is only achievable if we work collectively with people united by the same goals. With nearly one in two Canadians expected to be diagnosed with cancer in their lifetime, cancer affects us all.
At the cancer society, we believe research is the best way to accelerate progress so that more cancers can be prevented, and more people will not just survive cancer, but live longer and fuller lives.
Today more than 60 per cent of Canadians diagnosed with cancer will survive, compared with about 25 per cent in the 1940s, because of the advancements discovered through research. We are determined to empower people with cancer and ensure there are new treatment options for Canadians. One way we do this is through our support of life-saving clinical trials.
Published: November 27, 2019
Category: Group updates
We are coming up to a big holiday for American families. Please expect closure of U.S. Operations offices and laboratories on Thursday, November 28nd for the U.S. Thanksgiving. If you are planning to ship specimens to the U.S., please plan accordingly. Also remember that many of our U.S. collegues take additional holidays for an extra long weekend.
CCTG LY17 is a A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma. The trial is looking to determine the overall response rate (complete and partial response) to novel combination therapy in patients with relapsed and refractory aggressive B cell lymphoma. Dr. Kuruvilla and Dr. Crump stress the importance of this trial, collaboration within CCTG, and the overall benefit of cancer clinical trials. (NCT02436707)
CCTG is pleased to announce that the fall recipient of the Frances A. Shepherd Award is Dr. Assouline Division of Hematology McGill University, Jewish General Hospital Montreal, Quebec and the CCTG Hematologic Disease Site Chair
The CCTG ENC1 study, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC#776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer, has been centrally activated and open to accrual.